Advertisement

Chemotherapy effectiveness and age-group analysis of older adult patients with metastatic pancreatic cancer: A Japanese cancer registry cohort study

Published:August 03, 2022DOI:https://doi.org/10.1016/j.jgo.2022.07.010

      Abstract

      Introduction

      Although older adults aged ≥75 years comprise a substantial proportion of patients diagnosed with pancreatic cancer (PC), the effectiveness of chemotherapy in older adults with PC remains to be established.

      Materials and Methods

      This retrospective study examined the effectiveness of chemotherapy according to age in older adult patients with metastatic PC. We used a large database that combined three data sources (the hospital-based cancer registry database, Osaka Cancer Registry, and Japan's Diagnosis Procedure Combination) and extracted data from patients pathologically diagnosed with metastatic PC between 2013 and 2015 in 31 designated cancer care hospitals in Japan. Propensity score matching (PSM) was used to identify a cohort of patients with similar backgrounds. The effect of chemotherapy on overall survival (OS) was analyzed using the log-rank test.

      Results

      Compared with 687 younger patients (<75 years old), 276 older adult patients had significant impairments in activities of daily living and poorer prognoses (6.8 vs. 4.1 months, p < 0.001), with a lower frequency of chemotherapy (81.5% vs. 55.1%; p < 0.001). PSM of older adult patients showed that chemotherapy significantly contributed to a better prognosis (best supportive care, 2.6 months vs. chemotherapy, 5.8 months, p < 0.001). Age group analysis with PSM of five-year age ranges revealed that the median OS was significantly longer in the chemotherapy group among older adult patients aged <85 years.

      Discussion

      Chemotherapy provides a survival benefit in older adult patients with metastatic PC, and patients aged <85 years could be promising candidates for chemotherapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Fuchs H.E.
        • Jemal A.
        Cancer statistics, 2021.
        CA Cancer J Clin. 2021; 71: 7-33https://doi.org/10.3322/caac.21654
        • Okusaka T.
        • Furuse J.
        Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines.
        J Gastroenterol. 2020; 55: 369-382https://doi.org/10.1007/s00535-020-01666-y
        • Takada R.
        • Ikezawa K.
        • Daiku K.
        • Maeda S.
        • Abe Y.
        • Urabe M.
        • et al.
        The survival benefit of chemoradiotherapy following induction chemotherapy with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.
        Cancers (Basel). 2021; 13: 4733https://doi.org/10.3390/cancers13184733
        • Ikezawa K.
        • Kiyota R.
        • Takada R.
        • Daiku K.
        • Maeda S.
        • Imai T.
        • et al.
        Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancer.
        JGH Open. 2021; 5: 679-685https://doi.org/10.1002/jgh3.12555
        • Sung H.
        • Ferlay J.
        • Siegel R.L.
        • Laversanne M.
        • Soerjomataram I.
        • Jemal A.
        • et al.
        Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2021; 71: 209-249https://doi.org/10.3322/caac.21660
        • Ogden J.R.
        • Xie H.
        • Ma W.W.
        • Hubbard J.M.
        The management of older adults with pancreatic adenocarcinoma.
        Geriatrics (Basel). 2018; 3: 85https://doi.org/10.3390/geriatrics3040085
        • Okusaka T.
        • Nakamura M.
        • Yoshida M.
        • Kitano M.
        • Uesaka K.
        • Ito Y.
        • et al.
        Clinical practice guidelines for pancreatic cancer 2019 from the Japan pancreas society: a synopsis.
        Pancreas. 2020; 49: 326-335https://doi.org/10.1097/MPA.0000000000001513
        • Von Hoff D.D.
        • Ervin T.
        • Arena F.P.
        • Chiorean E.G.
        • Infante J.
        • Moore M.
        • et al.
        Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
        N Engl J Med. 2013; 369: 1691-1703https://doi.org/10.1056/NEJMoa1304369
        • Conroy T.
        • Desseigne F.
        • Ychou M.
        • Bouché O.
        • Guimbaud R.
        • Bécouarn Y.
        • et al.
        FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
        N Engl J Med. 2011; 364: 1817-1825https://doi.org/10.1056/NEJMoa1011923
        • Franck C.
        • Müller C.
        • Rosania R.
        • Croner R.S.
        • Pech M.
        • Venerito M.
        Advanced pancreatic ductal adenocarcinoma: moving forward.
        Cancers (Basel). 2020; 12: 1955https://doi.org/10.3390/cancers12071955
        • Ministry of Health Labour and Welfare
        Vital statistics.
        ([accessed 14 March 2022])
        • Yamagishi Y.
        • Higuchi H.
        • Izumiya M.
        • Sakai G.
        • Iizuka H.
        • Nakamura S.
        • et al.
        Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma.
        J Gastroenterol. 2010; 45: 1146-1154https://doi.org/10.1007/s00535-010-0258-9
        • Ishimoto U.
        • Kinoshita A.
        • Hirose Y.
        • Shibata K.
        • Ishii A.
        • Shoji R.
        • et al.
        The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients.
        Cancer Chemother Pharmacol. 2019; 84: 647-654https://doi.org/10.1007/s00280-019-03895-2
        • Hasegawa R.
        • Okuwaki K.
        • Kida M.
        • Yamauchi H.
        • Kawaguchi Y.
        • Matsumoto T.
        • et al.
        A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer.
        Int J Clin Oncol. 2019; 24: 1574-1581https://doi.org/10.1007/s10147-019-01511-0
        • Ibusuki M.
        • Inoue T.
        • Kitano R.
        • Sakamoto K.
        • Kimoto S.
        • Kobayashi Y.
        • et al.
        Gemcitabine plus nab-paclitaxel with initial dose reduction for older patients with advanced pancreatic cancer.
        J Geriatr Oncol. 2021; 12: 118-121https://doi.org/10.1016/j.jgo.2020.06.017
        • Kobayashi S.
        • Ueno M.
        • Ikeda M.
        • Ozaka M.
        • Sano Y.
        • Hirotani A.
        • et al.
        A multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer.
        Pancreas. 2020; 49: 187-192https://doi.org/10.1097/MPA.0000000000001484
        • Macchini M.
        • Chiaravalli M.
        • Zanon S.
        • Peretti U.
        • Mazza E.
        • Gianni L.
        • et al.
        Chemotherapy in elderly patients with pancreatic cancer: efficacy, feasibility and future perspectives.
        Cancer Treat Rev. 2019; 72: 1-6https://doi.org/10.1016/j.ctrv.2018.10.013
        • Xie H.
        • Liu J.
        • Ogden J.R.
        • Yin J.
        • Jatoi A.
        • Hubbard J.M.
        • et al.
        Survival benefit of combination chemotherapy in elderly patients with metastatic pancreatic ductal adenocarcinoma.
        Am J Clin Oncol. 2020; 43: 586-590https://doi.org/10.1097/COC.0000000000000708
        • Kuroda T.
        • Kumagi T.
        • Yokota T.
        • Azemoto N.
        • Hasebe A.
        • Seike H.
        • et al.
        Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients.
        BMC Gastroenterol. 2017; 17: 66https://doi.org/10.1186/s12876-017-0623-8
        • van der Geest L.G.M.
        • Haj Mohammad N.
        • Besselink M.G.H.
        • Lemmens V.E.P.P.
        • Portielje J.E.A.
        • van Laarhoven H.W.M.
        • et al.
        Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer.
        Cancer Med. 2017; 6: 2840-2849https://doi.org/10.1002/cam4.1240
        • Macarulla T.
        • Blanc J.-F.
        • Wang-Gillam A.
        • Chen L.-T.
        • Siveke J.T.
        • Mirakhur B.
        • et al.
        Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - a subgroup analysis of the pivotal NAPOLI-1 trial.
        J Geriatr Oncol. 2019; 10: 427-435https://doi.org/10.1016/j.jgo.2019.02.011
        • Quan H.
        • Li B.
        • Couris C.M.
        • Fushimi K.
        • Graham P.
        • Hider P.
        • et al.
        Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.
        Am J Epidemiol. 2011; 173: 676-682https://doi.org/10.1093/aje/kwq433
        • Quan H.
        • Sundararajan V.
        • Halfon P.
        • Fong A.
        • Burnand B.
        • Luthi J.C.
        • et al.
        Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
        Med Care. 2005; 43: 1130-1139https://doi.org/10.1097/01.mlr.0000182534.19832.83
        • Morishima T.
        • Matsumoto Y.
        • Koeda N.
        • Shimada H.
        • Maruhama T.
        • Matsuki D.
        • et al.
        Impact of comorbidities on survival in gastric, colorectal, and lung cancer patients.
        J Epidemiol. 2019; 29: 110-115https://doi.org/10.2188/jea.JE20170241
        • Mattei A.
        Estimating and using propensity score in presence of missing background data: an application to assess the impact of childbearing on wellbeing.
        Stat Methods Appl. 2009; 18: 257-273https://doi.org/10.1007/s10260-007-0086-0
        • Mokdad A.A.
        • Minter R.M.
        • Zhu H.
        • Augustine M.M.
        • Porembka M.R.
        • Wang S.C.
        • et al.
        Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis.
        J Clin Oncol. 2017; 35: 515-522https://doi.org/10.1200/JCO.2016.68.5081
        • Kanda Y.
        Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics.
        Bone Marrow Transplant. 2013; 48: 452-458https://doi.org/10.1038/bmt.2012.244
        • Rasmussen L.S.
        • Fristrup C.W.
        • Jensen B.V.
        • Pfeiffer P.
        • Weber B.
        • Yilmaz M.K.
        • et al.
        Initial treatment and survival in 4163 Danish patients with pancreatic cancer: a nationwide unselected real-world register study.
        Eur J Cancer. 2020; 129: 50-59https://doi.org/10.1016/j.ejca.2020.01.015
        • Garcia G.
        • Odaimi M.
        Systemic combination chemotherapy in elderly pancreatic cancer: a review.
        J Gastrointest Cancer. 2017; 48: 121-128https://doi.org/10.1007/s12029-017-9930-0
        • Lee S.Y.
        • Sissoko M.
        • Hartshorn K.L.
        Update on the management of pancreatic cancer in older adults.
        Curr Oncol Rep. 2016; 18: 60https://doi.org/10.1007/s11912-016-0547-4
        • Scheithauer W.
        • Putora P.M.
        • Grünberger B.
        • Eisterer W.
        • Wöll E.
        • Prager G.
        • et al.
        Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine.
        Therap Adv Gastroenterol. 2019; 12 (1756284819877635)https://doi.org/10.1177/1756284819877635
        • Locher C.
        • Fabre-Guillevin E.
        • Brunetti F.
        • Auroux J.
        • Delchier J.C.
        • Piedbois P.
        • et al.
        Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study.
        Crit Rev Oncol Hematol. 2008; 68: 178-182https://doi.org/10.1016/j.critrevonc.2008.06.010
        • Ishii H.
        • Yamashita N.
        • Ueno M.
        • Ohkawa S.
        • Saito A.M.
        • Sekimoto M.
        A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer patients aged ≥75 years: a study protocol for an open-label randomised feasibility study.
        BMJ Open Gastroenterol. 2018; 5e000187https://doi.org/10.1136/bmjgast-2017-000187
        • Jain R.
        • Vijayvergia N.
        • Devarajan K.
        • Lewis B.
        • Denlinger C.S.
        • Cohen S.J.
        • et al.
        Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era.
        J Geriatr Oncol. 2020; 11: 640-646https://doi.org/10.1016/j.jgo.2019.12.013
        • Li X.
        • Huang D.B.
        • Zhang Q.
        • Guo C.X.
        • Fu Q.H.
        • Zhang X.C.
        • et al.
        The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer.
        Pancreatology. 2020; 20: 95-100https://doi.org/10.1016/j.pan.2019.11.012
        • Mizrahi J.D.
        • Rogers J.E.
        • Hess K.R.
        • Wolff R.A.
        • Varadhachary G.R.
        • Javle M.M.
        • et al.
        Modified FOLFIRINOX in pancreatic cancer patients age 75 or older.
        Pancreatology. 2020; 20: 501-504https://doi.org/10.1016/j.pan.2020.01.005
        • Guion-Dusserre J.F.
        • Bertaut A.
        • Ghiringhelli F.
        • Vincent J.
        • Quipourt V.
        • Marilier S.
        • et al.
        Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy.
        World J Gastroenterol. 2016; 22: 9378-9386https://doi.org/10.3748/wjg.v22.i42.9378
        • Morishima T.
        • Sato A.
        • Nakata K.
        • Matsumoto Y.
        • Koeda N.
        • Shimada H.
        • et al.
        Barthel index-based functional status as a prognostic factor in young and middle-aged adults with newly diagnosed gastric, colorectal and lung cancer: a multicentre retrospective cohort study.
        BMJ Open. 2021; 11e046681https://doi.org/10.1136/bmjopen-2020-046681
        • Nishikawa T.
        • Fujita T.
        • Morishima T.
        • Okawa S.
        • Hino T.
        • Yasui T.
        • et al.
        Prognostic effect of incidental pulmonary embolism on long-term mortality in cancer patients.
        Circ J. 2021; https://doi.org/10.1253/circj.CJ-20-1160
        • Morishima T.
        • Sato A.
        • Nakata K.
        • Miyashiro I.
        Geriatric assessment domains to predict overall survival in older cancer patients: an analysis of functional status, comorbidities, and nutritional status as prognostic factors.
        Cancer Med. 2020; 9: 5839-5850https://doi.org/10.1002/cam4.3205
        • Kawamura H.
        • Morishima T.
        • Sato A.
        • Honda M.
        • Miyashiro I.
        Effect of adjuvant chemotherapy on survival benefit in stage III colon cancer patients stratified by age: a Japanese real-world cohort study.
        BMC Cancer. 2020; 20: 19https://doi.org/10.1186/s12885-019-6508-1